Literature DB >> 21964640

Penicillin: the medicine with the greatest impact on therapeutic outcomes.

Nelson Kardos1, Arnold L Demain.   

Abstract

The principal point of this paper is that the discovery of penicillin and the development of the supporting technologies in microbiology and chemical engineering leading to its commercial scale production represent it as the medicine with the greatest impact on therapeutic outcomes. Our nomination of penicillin for the top therapeutic molecule rests on two lines of evidence concerning the impact of this event: (1) the magnitude of the therapeutic outcomes resulting from the clinical application of penicillin and the subsequent widespread use of antibiotics and (2) the technologies developed for production of penicillin, including both microbial strain selection and improvement plus chemical engineering methods responsible for successful submerged fermentation production. These became the basis for production of all subsequent antibiotics in use today. These same technologies became the model for the development and production of new types of bioproducts (i.e., anticancer agents, monoclonal antibodies, and industrial enzymes). The clinical impact of penicillin was large and immediate. By ushering in the widespread clinical use of antibiotics, penicillin was responsible for enabling the control of many infectious diseases that had previously burdened mankind, with subsequent impact on global population demographics. Moreover, the large cumulative public effect of the many new antibiotics and new bioproducts that were developed and commercialized on the basis of the science and technology after penicillin demonstrates that penicillin had the greatest therapeutic impact event of all times. © Springer-Verlag 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21964640     DOI: 10.1007/s00253-011-3587-6

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  27 in total

1.  A new antibiotic kills pathogens without detectable resistance.

Authors:  Losee L Ling; Tanja Schneider; Aaron J Peoples; Amy L Spoering; Ina Engels; Brian P Conlon; Anna Mueller; Till F Schäberle; Dallas E Hughes; Slava Epstein; Michael Jones; Linos Lazarides; Victoria A Steadman; Douglas R Cohen; Cintia R Felix; K Ashley Fetterman; William P Millett; Anthony G Nitti; Ashley M Zullo; Chao Chen; Kim Lewis
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

2.  Analogs of the Cathelicidin-Derived Antimicrobial Peptide PMAP-23 Exhibit Improved Stability and Antibacterial Activity.

Authors:  Yongqing Liu; Tengfei Shen; Liangliang Chen; Jiangfei Zhou; Chen Wang
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

3.  Crowdsourcing natural products discovery to access uncharted dimensions of fungal metabolite diversity.

Authors:  Lin Du; Andrew J Robles; Jarrod B King; Douglas R Powell; Andrew N Miller; Susan L Mooberry; Robert H Cichewicz
Journal:  Angew Chem Int Ed Engl       Date:  2013-11-27       Impact factor: 15.336

4.  Substitutions in PBP2b from β-Lactam-resistant Streptococcus pneumoniae Have Different Effects on Enzymatic Activity and Drug Reactivity.

Authors:  Philippe Calvez; Eefjan Breukink; David I Roper; Mélanie Dib; Carlos Contreras-Martel; André Zapun
Journal:  J Biol Chem       Date:  2017-01-06       Impact factor: 5.157

Review 5.  Targets for Combating the Evolution of Acquired Antibiotic Resistance.

Authors:  Matthew J Culyba; Charlie Y Mo; Rahul M Kohli
Journal:  Biochemistry       Date:  2015-06-05       Impact factor: 3.162

6.  Phylogeny-driven target selection for large-scale genome-sequencing (and other) projects.

Authors:  Markus Göker; Hans-Peter Klenk
Journal:  Stand Genomic Sci       Date:  2013-05-20

Review 7.  The multifaceted role of commensal microbiota in homeostasis and gastrointestinal diseases.

Authors:  Marcelo José Barbosa Silva; Matheus Batista Heitor Carneiro; Brunna dos Anjos Pultz; Danielle Pereira Silva; Mateus Eustáquio de Moura Lopes; Liliane Martins dos Santos
Journal:  J Immunol Res       Date:  2015-02-22       Impact factor: 4.818

Review 8.  Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing.

Authors:  Natalie K Boyd; Chengwen Teng; Christopher R Frei
Journal:  Front Cell Infect Microbiol       Date:  2021-05-17       Impact factor: 5.293

Review 9.  Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches.

Authors:  José E Belizário; Mauro Napolitano
Journal:  Front Microbiol       Date:  2015-10-06       Impact factor: 5.640

10.  Characterization of the antibacterial activity from ethanolic extracts of the botanical, Larrea tridentata.

Authors:  Tiffany Turner; Guillermo Ruiz; Johanne Gerstel; Jeffrey Langland
Journal:  BMC Complement Med Ther       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.